BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27832516)

  • 1. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis.
    Komatsu N; Kirito K; Shimoda K; Ishikawa T; Ohishi K; Ohyashiki K; Takahashi N; Okada H; Amagasaki T; Yonezu T; Akashi K
    Int J Hematol; 2017 Mar; 105(3):309-317. PubMed ID: 27832516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
    Talpaz M; Paquette R; Afrin L; Hamburg SI; Prchal JT; Jamieson K; Terebelo HR; Ortega GL; Lyons RM; Tiu RV; Winton EF; Natrajan K; Odenike O; Claxton D; Peng W; O'Neill P; Erickson-Viitanen S; Leopold L; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
    J Hematol Oncol; 2013 Oct; 6(1):81. PubMed ID: 24283202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Koumenis IL; Sun W; Sandor V; Kantarjian HM
    N Engl J Med; 2012 Mar; 366(9):799-807. PubMed ID: 22375971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
    Couban S; Benevolo G; Donnellan W; Cultrera J; Koschmieder S; Verstovsek S; Hooper G; Hertig C; Tandon M; Dimier N; Malhi V; Passamonti F
    J Hematol Oncol; 2018 Sep; 11(1):122. PubMed ID: 30249277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study.
    Talpaz M; Erickson-Viitanen S; Hou K; Hamburg S; Baer MR
    J Hematol Oncol; 2018 Aug; 11(1):101. PubMed ID: 30086777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Sun W; Sandor V; Kantarjian HM
    Haematologica; 2013 Dec; 98(12):1865-71. PubMed ID: 24038026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing.
    Mesa RA; Cortes J
    J Hematol Oncol; 2013 Oct; 6():79. PubMed ID: 24283870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose ruxolitinib for improving leukopaenia and reducing recurrent infections associated with myelofibrosis.
    Islam R; Yellu MR; Rafiullah ; Shaw GR
    BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23704469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.
    Yacoub A; Odenike O; Verstovsek S
    Curr Hematol Malig Rep; 2014 Dec; 9(4):350-9. PubMed ID: 25145552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.
    Bose P; Swaminathan M; Pemmaraju N; Ferrajoli A; Jabbour EJ; Daver NG; DiNardo CD; Alvarado Y; Yilmaz M; Huynh-Lu J; Qiao W; Wang X; Matamoros A; Zhou L; Pierce S; Schroeder KD; Kantarjian HM; Verstovsek S
    Leuk Lymphoma; 2019 Jul; 60(7):1767-1774. PubMed ID: 30632841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.
    Koschmieder S; Isfort S; Schulte C; Jacobasch L; Geer T; Reiser M; Koenigsmann M; Heinrich B; Wehmeyer J; von der Heyde E; Tesch H; Gröschl B; Bachhuber P; Großer S; Pahl HL
    Ann Hematol; 2023 Dec; 102(12):3383-3399. PubMed ID: 37792065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
    Yacoub A; Borate U; Rampal RK; Ali H; Wang ES; Gerds AT; Hobbs G; Kremyanskaya M; Winton E; O'Connell C; Goel S; Oh ST; Schiller G; McCloskey J; Palmer J; Holmes H; Hager S; Assad A; Erickson-Viitanen S; Zhou F; Daver N
    Blood Adv; 2024 Mar; 8(6):1515-1528. PubMed ID: 38290135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to.
    Li Y; Zhu S; Liu W; Ming J; Wang X; Hu X
    Ann Hematol; 2020 Jun; 99(6):1161-1176. PubMed ID: 32333155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib.
    Kuykendall AT; Ball S; Mora B; Mo Q; Al Ali N; Maffioli M; Auteri G; Mazzoni C; Palumbo GA; Duminuco A; Longo A; Elli EM; Passamonti F; Palandri F; Komrokji R
    JCO Precis Oncol; 2024 Mar; 8():e2300593. PubMed ID: 38484210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study.
    Palandri F; Auteri G; Abruzzese E; Caocci G; Bonifacio M; Mendicino F; Latagliata R; Iurlo A; Branzanti F; Garibaldi B; Trawinska MM; Cattaneo D; Krampera M; Mulas O; Martino EA; Cavo M; Vianelli N; Impera S; Efficace F; Heidel F; Breccia M; Elli EM; Palumbo GA
    Ann Hematol; 2024 Jun; 103(6):1931-1940. PubMed ID: 38478023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohort.
    Tavares R; Souza CA; Paley C; Bouard C; Tiwari R; Pasquini R
    Hematol Transfus Cell Ther; 2020; 42(1):46-53. PubMed ID: 31235325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib associated psoas muscle tuberculosis abscess in a primary myelofibrosis woman: A case report and literature review.
    Chen CY; Chen TC
    Medicine (Baltimore); 2024 Apr; 103(14):e37653. PubMed ID: 38579059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial.
    Verstovsek S; Foltz L; Gupta V; Hasserjian R; Manshouri T; Mascarenhas J; Mesa R; Pozdnyakova O; Ritchie E; Veletic I; Gamel K; Hamidi H; Han L; Higgins B; Trunzer K; Uguen M; Wang D; El-Galaly TC; Todorov B; Gotlib J
    Haematologica; 2023 Oct; 108(10):2730-2742. PubMed ID: 37165840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
    Verstovsek S; Mesa R; Gupta V; Lavie D; Dubruille V; Cambier N; Platzbecker U; Hus M; Xicoy B; Oh ST; Kiladjian JJ; Vannucchi AM; Gerds A; Egyed M; Mayer J; Sacha T; Kawashima J; Morris M; Huang M; Harrison C
    Blood Adv; 2023 Jul; 7(14):3582-3591. PubMed ID: 37042865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.
    Maffioli M; Giorgino T; Mora B; Iurlo A; Elli E; Finazzi MC; Caramella M; Rumi E; Carraro MC; Polverelli N; D'Adda M; Malato S; Rossi M; Molteni A; Vismara A; Sissa C; Spina F; Anghilieri M; Cattaneo D; Renso R; Bellini M; Pioltelli ML; Cavalloni C; Barraco D; Accetta R; Bertù L; Della Porta MG; Passamonti F
    Blood Adv; 2019 Nov; 3(21):3196-3200. PubMed ID: 31698448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.